Damora Therapeutics (DMRA) EBT (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of EBT data on file, last reported at -$27.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 996.05% year-over-year to -$27.7 million; the trailing twelve-month figure through Mar 2026 stood at -$231.1 million (down 3152.27% YoY), and the FY2025 full-year result was -$205.9 million, down 1948.43% from the prior year.
• EBT for Q1 2026 stood at -$27.7 million, up from -$196.8 million in the prior quarter.
• Across five years, EBT topped out at $4.6 million in Q4 2024 and bottomed at -$196.8 million in Q4 2025.
• The 5-year median for EBT is -$8.1 million (2023), against an average of -$20.2 million.
• The widest annual swing landed in 2024, when EBT soared 170.98%; it then sank 4382.68% in 2025.
• A 5-year view of EBT shows it stood at -$13.5 million in 2022, then soared by 52.13% to -$6.5 million in 2023, then jumped by 170.98% to $4.6 million in 2024, then tumbled by 4382.68% to -$196.8 million in 2025, then surged by 85.91% to -$27.7 million in 2026.
• The last three EBT figures came in at -$27.7 million (Q1 2026), -$196.8 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.

Peer Comparison